Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

Cladribine (2-chlorodeoxyadenosine, 2CdA) is one of the most effective disease-modifying drugs for multiple sclerosis (MS). Cladribine is a synthetic purine nucleoside analog that induces cell death of lymphocytes and oral cladribine treatment leads to a long-lasting disease stabilization, potential...

Full description

Bibliographic Details
Main Authors: Tiago Medeiros-Furquim, Sinan Ayoub, Laura J. Johnson, Andrea Aprico, Eze Nwoke, Michele D. Binder, Trevor J. Kilpatrick
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
cladribine
2-chlorodeoxyadenosine (2-CdA)
innate immunity
neuroinflammation
monocyte
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.678817/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.678817/full

Similar Items